Akero Therapeutics, Inc. (NASDAQ: AKRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
Akero Therapeutics, Inc. (NASDAQ: AKRO) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $65.00 price target on the stock.
Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024 [Yahoo! Finance]
Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024
Akero Therapeutics to Present at the Jefferies London Healthcare Conference